Relay Therapeutics (RLAY) AI Stock Analysis

• Market Cap: $649.78M
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: -78.26%
• EPS Growth: 15.41%
• Country: US
• Employees: 259
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.46
• Shares Outstanding: 171,444,960
• 10 Day Avg. Volume: 2,095,126
• 30 Day Avg. Volume: 1,692,465
• PEG Ratio: -0.27
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 8.80
• Enterprise Value/Gross Profit: -593.43
• Enterprise Value/Ebitda: -0.37
• 1Y Price Target: $12.38
• Price Target Upside: 226.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 57 Neutral
• Price Target: $4.00 ▲(5.54%Upside)

Relay Therapeutics' overall score reflects a balance of strengths in technical momentum and strategic cost reductions against weaknesses in financial performance and valuation. The recent lease agreement and analyst optimism are positive, but the company's financial challenges remain a concern.

Positive Factors

Financial Stability

The reduction in workforce is expected to extend the cash runway into 2029, improving financial stability.

Innovative Drug Development

Relay Therapeutics Inc is gaining attention due to its innovative approach in drug development.

Negative Factors

Competitive Landscape

The competitive landscape in the biotechnology sector poses a challenge for Relay Therapeutics' market position.

Stock Performance

The stock is down -20% vs XBI -8% YTD, likely due to a lack of clinical catalysts in the upcoming 12 months and macro.

Relay Therapeutics Business Overview & Revenue Model

Company Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Relay Therapeutics generates revenue through a combination of collaborative partnerships, licensing agreements, and its proprietary drug development pipeline. The company partners with other pharmaceutical firms to co-develop and commercialize therapies, sharing the potential profits while mitigating risks and costs associated with drug development. Additionally, Relay Therapeutics may receive milestone payments and royalties from its partners based on the successful development and commercialization of partnered therapies. As the company's own drug candidates advance through clinical trials, successful commercialization of these drugs would provide significant revenue streams through sales. Furthermore, Relay Therapeutics might engage in strategic collaborations that can offer upfront payments, research funding, and other financial incentives, contributing to its overall earnings.

Relay Therapeutics Financial Statement Overview

Summary

Relay Therapeutics shows significant revenue volatility with consistent losses, negative net profit margins, and cash flow challenges. Despite a strong balance sheet with high equity ratios and low leverage, the company's profitability and cash generation are critical concerns.

Income Statement

Relay Therapeutics has experienced volatility in revenue, with significant fluctuations over the years. The gross profit margin is positive in recent years, but the company consistently reports negative net income, resulting in a negative net profit margin. EBIT and EBITDA margins are also negative, indicating operational challenges. The revenue has shown growth over the past year, but the overall trajectory remains uncertain.

Balance Sheet

The balance sheet of Relay Therapeutics is relatively strong with a high equity ratio, indicating a larger proportion of assets financed by equity. The company has a low debt-to-equity ratio, suggesting manageable leverage. However, the consistent net losses impact the return on equity negatively. Overall, the company maintains a stable financial position despite ongoing losses.

Cash Flow

Relay Therapeutics has faced challenges generating positive cash flow, with negative free and operating cash flows. The free cash flow has been declining, indicating cash constraints. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting profits to cash. While the company has been able to access financing, it remains cash flow negative.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.01M	25.55M	1.38M	3.03M	82.65M
Gross Profit	4.54M	20.28M	-2.75M	-896.00K	79.11M
EBITDA	-372.47M	-374.15M	-306.82M	-222.18M	-52.25M
Net Income	-337.71M	-341.97M	-254.26M	-496.81M	-49.01M
Balance Sheet
Total Assets	871.30M	843.98M	1.10B	1.01B	799.83M
Cash, Cash Equivalents and Short-Term Investments	781.32M	750.09M	998.92M	958.07M	678.06M
Total Debt	48.50M	53.47M	57.74M	22.90M	24.42M
Total Liabilities	93.50M	91.98M	149.55M	110.64M	36.54M
Stockholders Equity	777.79M	752.00M	950.22M	897.81M	763.29M
Cash Flow
Free Cash Flow	-251.13M	-304.44M	-238.55M	-77.88M	-104.42M
Operating Cash Flow	-249.11M	-300.32M	-229.49M	-74.41M	-102.49M
Investing Cash Flow	-41.08M	257.63M	-188.75M	-479.51M	81.67M
Financing Cash Flow	270.15M	34.75M	289.91M	388.09M	426.51M

Relay Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLAY, the sentiment is Positive. The current price of 3.79 is above the 20-day moving average (MA) of 3.57, above the 50-day MA of 3.29, and below the 200-day MA of 4.06, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 61.27 is Neutral, neither overbought nor oversold. The STOCH value of 57.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLAY.

Relay Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLAY	57 Neutral	$649.78M	―	-45.46%	―	-78.26%	15.41%
TBPH	57 Neutral	$565.02M	―	-31.46%	―	6.11%	-37.79%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
KROS	51 Neutral	$586.08M	―	0.71%	―	91657.69%	97.21%
PGEN	50 Neutral	$490.00M	―	-278.55%	―	-22.76%	-46.69%
TYRA	41 Neutral	$574.85M	―	-27.04%	―	―	6.72%
SION	―	$872.34M	―		―	―	―

Relay Therapeutics Corporate Events

Claire Mazumdar Joins Relay Therapeutics as Director

On June 8, 2025, Jami Ruben resigned from the Board of Directors and Audit Committee of Relay Therapeutics, with no disputes involved. Subsequently, on June 9, 2025, Claire Mazumdar was appointed as a Class III Director and chair of the Audit Committee. Her appointment is expected to bring strategic guidance as Relay Therapeutics prepares for its Phase 3 ReDiscover-2 trial in breast cancer, potentially impacting the company’s operations and market positioning.

The most recent analyst rating on (RLAY) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.

Relay Therapeutics Holds 2025 Annual Stockholder Meeting

On June 6, 2025, Relay Therapeutics held its 2025 Annual Meeting of Stockholders, where three key proposals were voted on. The stockholders elected Alexis Borisy and Mark Murcko, Ph.D., as class II directors for a three-year term, approved executive compensation on a non-binding advisory basis, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its future direction and stakeholder confidence.

The most recent analyst rating on (RLAY) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.

Relay Therapeutics Announces Lease Termination Agreement

On June 3, 2025, Relay Therapeutics, Inc. announced a lease amendment with ARE MA Region No. 58, LLC, which will accelerate the termination of its Binney Street Lease in Cambridge, Massachusetts. This strategic move involves transitioning to a smaller office space at Kendall Square, resulting in a significant reduction of approximately $16 million in rent expenses over the lease commitments. The company continues to maintain its corporate headquarters at 60 Hampshire Street, Cambridge.

The most recent analyst rating on (RLAY) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.